China Pharma receives noncompliance notice from NYSE American

China Pharma Holdings announced that on December 1, 2022, received a notification from the NYSE American LLC stating that the company was not in compliance with a certain NYSE American continued listing standard relating to stockholders’ equity, or Section 1003(a)(ii) of the NYSE American Company Guide, which requires an issuer to have stockholders’ equity of $4M or more if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. The Deficiency Letter noted that company had stockholders’ equity of $2.8M as of September 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended December 31, 2021.